These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 39084852)
1. Targeted Liposomal Co-delivery of an Immunogenic Cell Death Inducer and a Toll-Like Receptor 4 Agonist for Enhanced Cancer Chemo-immunotherapy. Park H; Lee S; Son MK; Kang I; Surwase SS; Song YG; Lee HK; Lee YK; Kim YC ACS Appl Mater Interfaces; 2024 Aug; 16(32):41810-41818. PubMed ID: 39084852 [TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959 [TBL] [Abstract][Full Text] [Related]
3. Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy. Li J; Zhou S; Yu J; Cai W; Yang Y; Kuang X; Liu H; He Z; Wang Y J Control Release; 2021 Jul; 335():306-319. PubMed ID: 34081995 [TBL] [Abstract][Full Text] [Related]
4. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy. Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668 [TBL] [Abstract][Full Text] [Related]
5. Sequentially pH-Responsive Drug-Delivery Nanosystem for Tumor Immunogenic Cell Death and Cooperating with Immune Checkpoint Blockade for Efficient Cancer Chemoimmunotherapy. Jiang M; Chen W; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W ACS Appl Mater Interfaces; 2021 Sep; 13(37):43963-43974. PubMed ID: 34506118 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo-immunotherapy. Jiang M; Zeng J; Zhao L; Zhang M; Ma J; Guan X; Zhang W Nanoscale; 2021 Oct; 13(41):17218-17235. PubMed ID: 34643196 [TBL] [Abstract][Full Text] [Related]
7. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway. Liu D; Li K; Gong L; Fu L; Yang D Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659 [TBL] [Abstract][Full Text] [Related]
8. Synthetic Immunogenic Cell Death Mediated by Intracellular Delivery of STING Agonist Nanoshells Enhances Anticancer Chemo-immunotherapy. Chattopadhyay S; Liu YH; Fang ZS; Lin CL; Lin JC; Yao BY; Hu CJ Nano Lett; 2020 Apr; 20(4):2246-2256. PubMed ID: 32160474 [TBL] [Abstract][Full Text] [Related]
9. Self-Assembled Immunostimulatory Tetrahedral Framework Nucleic Acid Vehicles for Tumor Chemo-immunotherapy. Liu M; Hao L; Zhao D; Li J; Lin Y ACS Appl Mater Interfaces; 2022 Aug; 14(34):38506-38514. PubMed ID: 35973112 [TBL] [Abstract][Full Text] [Related]
10. Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo. Nguyen VD; Min HK; Kim CS; Han J; Park JO; Choi E Colloids Surf B Biointerfaces; 2019 Jan; 173():539-548. PubMed ID: 30343218 [TBL] [Abstract][Full Text] [Related]
11. Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy. Wang Y; Wang Z; Chen B; Yin Q; Pan M; Xia H; Zhang B; Yan Y; Jiang Z; Zhang Q; Wang Y Nano Lett; 2021 May; 21(10):4371-4380. PubMed ID: 33984236 [TBL] [Abstract][Full Text] [Related]
12. Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade. Zhang B; Li N; Gao J; Zhao Y; Jiang J; Xie S; Zhang C; Zhang Q; Liu L; Wang Z; Ji D; Wu L; Ren R J Exp Clin Cancer Res; 2024 Feb; 43(1):51. PubMed ID: 38373953 [TBL] [Abstract][Full Text] [Related]
13. Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors. Mei KC; Liao YP; Jiang J; Chiang M; Khazaieli M; Liu X; Wang X; Liu Q; Chang CH; Zhang X; Li J; Ji Y; Melano B; Telesca D; Xia T; Meng H; Nel AE ACS Nano; 2020 Oct; 14(10):13343-13366. PubMed ID: 32940463 [TBL] [Abstract][Full Text] [Related]
14. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233 [TBL] [Abstract][Full Text] [Related]
15. Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy. Li C; Wang L; Li Z; Li Z; Zhang K; Cao L; Wang Z; Shen C; Chen L Int J Pharm; 2024 Feb; 651():123729. PubMed ID: 38142016 [TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment-responsive spherical nucleic acid nanoparticles for enhanced chemo-immunotherapy. Ma B; Ma Y; Deng B; Xiao P; Huang P; Wang D; Liu L J Nanobiotechnology; 2023 May; 21(1):171. PubMed ID: 37237292 [TBL] [Abstract][Full Text] [Related]
17. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy. Wei X; Liu L; Li X; Wang Y; Guo X; Zhao J; Zhou S J Control Release; 2019 Nov; 313():42-53. PubMed ID: 31629039 [TBL] [Abstract][Full Text] [Related]
18. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death. Wu S; Liu D; Li W; Song B; Chen C; Chen D; Hu H Int J Pharm; 2021 Apr; 598():120333. PubMed ID: 33540008 [TBL] [Abstract][Full Text] [Related]
19. Tumor-derived nanovesicles enhance cancer synergistic chemo-immunotherapy by promoting cGAS/STING pathway activation and immunogenetic cell death. Guo Y; Qian R; Li Z; Lv T; Yang C; Li W; Pan T; Hou X; Wang Z Life Sci; 2024 Jul; 348():122687. PubMed ID: 38718856 [TBL] [Abstract][Full Text] [Related]
20. A multi-mode Rhein-based nano-platform synergizing ferrotherapy/chemotherapy-induced immunotherapy for enhanced tumor therapy. Zhu X; Xie L; Tian J; Jiang Y; Song E; Song Y Acta Biomater; 2024 May; 180():383-393. PubMed ID: 38570106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]